National Covid-19 Immunisation Programme coordinating minister Khairy Jamaluddin said so far the American company was the only pharmaceutical company that had preliminary test findings on this age group.

“Pfizer has informed us that they will be sending information on ongoing clinical trials conducted on children aged 12 to 15 to the United States Food and Drug Administration.

“They (Pfizer) will also submit the information to our National Pharmaceutical Regulatory Agency (NPRA),” he told reporters at a press conference after the Kedah-level Covid-19 national immunisation task force meeting here today.

He said that after obtaining data on the clinical trials, NPRA would determine whether the Covid-19 vaccine manufactured by the company could be used to inoculate adolescents in the country.

“Most of our vaccine orders are from Pfizer and we may be able to ask for more (doses) from Pfizer after this if the vaccine can be used on teenagers,” he said.

However, Khairy said it could not be implemented in the near future as the clinical trials would take a long time to complete.

Meanwhile, he said seven more vaccination centres would be opened in Kedah starting May 1 to facilitate recipients to get their jabs under phase two of the vaccination exercise.

“Previously, we opened five vaccination centres in Kedah. Apart from that, we have four special vaccination centres in Kedah, namely Sultanah Bahiyah Hospital, Alor Setar; Sultan Abdul Halim Hospital, Sungai Petani; Kulim Hospital and Sultanah Maliha Hospital, Langkawi.”

Khairy said these special vaccination centres were set aside for high-risk groups with allergies, immune system problems and who had a history of bleeding.

CLICK HERE FOR THE LATEST DATA ON THE COVID-19 SITUATION IN MALAYSIA